Animace načítání

Stránka se připravuje...

Přihlásit se Registrovat se
29 005 právních předpisů

Další údaje zde

Technická podpora

Poskytujeme technickou podporu zdarma

Zavolejte nám

+420 777 717 492

Plné znění - 32020R1182

  1. Úvodní strana
  2. Právní předpisy EU
  3. Plné znění - 32020R1182

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Chci získat výhodný přístup

NAŘÍZENÍ XXXXXX V XXXXXXXXX XXXXXXXXX (XX) 2020/1182

xx dne 19. xxxxxx 2020,

xxxxxx xx xxx xxxxx xxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxxx xxxxxxx xxxx xxxx 3 xxxxxxx XX xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady (XX) x. 1272/2008 x xxxxxxxxxxx, xxxxxxxxxx a xxxxxx látek x xxxxx

(Xxxx s xxxxxxxx xxx XXX)

XXXXXXXX XXXXXX,

x xxxxxxx xx Xxxxxxx x xxxxxxxxx Xxxxxxxx xxxx,

x xxxxxxx na xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (ES) x. 1272/2008 xx xxx 16. prosince 2008 x klasifikaci, xxxxxxxxxx x xxxxxx xxxxx a směsí, x xxxxx x xxxxxxx xxxxxxx 67/548/EHS x 1999/45/ES x x xxxxx nařízení (XX) x. 1907/2006&xxxx;(1), x xxxxxxx na xx. 37 odst. 5 xxxxxxxxx xxxxxxxx,

xxxxxxxx x xxxxx důvodům:

(1)

Tabulka 3 v xxxxx 3 přílohy XX xxxxxxxx (ES) č. 1272/2008 xxxxxxxx xxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxx nebezpečných xxxxx xx xxxxxxx xxxxxxxx xxxxxxxxxxx v částech 2 xx 5 xxxxxxx X xxxxxxxxx xxxxxxxx.

(2)

Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx („agentura“) xxxx v xxxxxxx x xxxxxxx 37 xxxxxxxx (XX) č. 1272/2008 předloženy návrhy xx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx x označení xxxxxxxxx látek a xxxxxxxxxxx xxxx zrušení xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxxx xxxxx. Xx xxxxxxx xxxxxxxxxx&xxxx;(2) k těmto xxxxxxx, xxxxx xxxxx Xxxxx xxx xxxxxxxxxx xxxxx („RAC“) xxxxxxxx, xxxxx x připomínek xxxxxxxxxxxx xxxxx, xx xxxxxx zavést, xxxxxxxxxxxx xx xxxxxx xxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxx. Xxxxxxx xxxxxxxxxx výboru XXX xxxx:

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx kyseliny dusičné... %[X ≤ 70 %],

—

xxxxxxxxxx ze dne 9. xxxxxx 2018 xxxxxxx xxxxxx x xxxxxxx xxxxxxx (o xxxxxxx &xx; 3 μx,xxxxx > 5 μx x xxxxxx xxxxx ≥ 3:1),

—

stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxx, trimethoxy(vinyl)silanu,

—

stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxxx, 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxx-xxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 ohledně granulované xxxx,

—

xxxxxxxxxx xx dne 30. listopadu 2018 xxxxxxx bis (X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)-xxxx, xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxxx, [Xx-XXX],

—

xxxxxxxxxx ze xxx 14. xxxx 2018 xxxxxxx dioktyltin-dilaurátu, [1] xxxxxxxx, xxxxxxx-, xxx(xxxx acyloxy) xxxxxxxx [2],

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx[xxx,x]xxxxxxxx, dibenzo[a,l]pyrenu,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx (ISO), (1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorbenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyklopentanolu,

—

stanovisko xx dne 8. xxxxxx 2018 xxxxxxx xxx(2-(2-xxxxxxxxxxxxx)xxxxx)xxxxxx, tetraglymu,

—

stanovisko ze xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxx (XXX), (2RS,3RS)-1-(4-chlorofenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-olu,

—

stanovisko xx xxx 8. června 2018 xxxxxxx 2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 ohledně xxxxxxxxx, (2E)-3,7-dimethylokta-2,6-dien-1-olu,

—

stanovisko xx xxx 28. xxxxx 2019 ohledně 2-(4-xxxx-xxxxxxxxxxx)xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 9. xxxxxx 2018 ohledně XXXX-xxxxxxxxxx (XXX), X-xxxxx (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxxx, X-xxxxx 4-xxxxx-x-xxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 9. xxxxxx 2018 ohledně xxxxxxxxxx-xxxxxxx,

—

xxxxxxxxxx xx xxx 14. září 2018 xxxxxxx 4-{[(6-xxxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xxx, xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx-xxxxxxx (XXX), xxxxxx 4- [(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně X-(+)-xxxxxx xxxxxxxx, (2X)-2-xxxxxxxxxxxxxxxx xxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx 2-xxxxxxxxxxxx-xxxxxxxx,

—

xxxxxxxxxx ze xxx 8. června 2018 xxxxxxx glyoxylové xxxxxxxx …%,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx, [xxxxxxxxxxx xxxxxxxx x xxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně (xxxxx-XXX-xxxxx)xxxxxxxxxxx xxxxxxxxxx, cyklohexyl(hydroxy)diazen-1-oxidu, xxxxxxxx xxxx, [K-HDO],

—

stanovisko xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxxxx-xxxxxxxxxxx, X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxxx, xxxxxxxxxxx-xxxxx-xxxxxxx [XXX],

—

xxxxxxxxxx xx dne 9. března 2018 xxxxxxx (2XX)-2-[4-(4-xxxxxxxxxxx)-2(xxxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xxx, mefentriflukonazolu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxx (XXX), 1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxx-xxxxx, (T-4)-bis[1-(hydroxy-kappa-O)pyridin-2(1H)-thionát-kappa-S]zinku,

—

stanovisko xx xxx 30. listopadu 2018 xxxxxxx 3-xxxxx-4-(xxxxxxxxxxx)-1-[3-xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xxx, xxxxxxxxxxxxxxx (ISO),

—

stanovisko xx xxx 30. xxxxxxxxx 2018 ohledně 4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXXXX],

—

xxxxxxxxxx ze xxx 8. června 2018 xxxxxxx 2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xxx, [XXXX],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxxx, fluxapyroxadu,

—

stanovisko ze xxx 8. xxxxxx 2018 ohledně N-(hydroxymethyl)akrylamidu, xxxxxxxxxxxxxxxxxx, [XXX],

—

xxxxxxxxxx ze xxx 15. října 2018 xxxxxxx 5-fluor-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)fenyl]-1H-pyrazol-4-karboxamidu, 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx (XXX), xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (XXX), X-xxxxx-4,5-xxxxxxxx-2(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx dne 9. xxxxxx 2018 xxxxxxx xxxxxxx, xxxxxxx [olej xxxxxxxx xx xxxxxxx xx xxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxx xxxxxxxx, xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxx xxxxxxxxx],

—

xxxxxxxxxx xx xxx 8. června 2018 ohledně xxxxxxxx xxxxxxx …%[X&xx; 70 %],

—

xxxxxxxxxx x 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxx, [X4],

—

xxxxxxxxxx ze xxx 30. listopadu 2018 xxxxxxx xxxxxxxxx-xxxxxxx (XXX), O-[2-(diethylamin)-6-methylpyrimidin-4-yl]-O,O-dimethyl-fosforthioátu,

—

stanovisko xx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx,

—

xxxxxxxxxx ze xxx 14. září 2018 ohledně dichlordioktylstannanu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 ohledně 2-xxxxxxxxxx-10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxx-xxxxxxxxx, [XXXX],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně xxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx 2-xxxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx xxx 30. listopadu 2018 ohledně m-bis(2,3-epoxypropoxy)benzenu, xxxxxxxxxx-xxxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx dne 14. září 2018 xxxxxxx xxxxxxxxxx-xxxxxxx (XXX), xxxxxx 2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylkarbamoylsulfamoyl]benzoátu,

—

stanovisko ze xxx 8. června 2018 ohledně xxxxxxxxxxxxx (XXX), xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), (RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl-methansulfonátu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2,4-xxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxx (XXX), 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (XXX), 2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXX],

—

xxxxxxxxxx xx xxx 14. xxxx 2018 ohledně xxxxxxxxxx (XXX), 3-hydroxy-5-methylisoxazolu,

—

stanovisko xx xxx 30. listopadu 2018 ohledně xxxxxxxxxxxx (XXX), xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 9. března 2018 ohledně xxxxxxxxxxx (XXX), (X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxx-xxxxx)-1,2,4-xxxxxxx-3(2X)-xxx,

—

xxxxxxxxxx xx xxx 9. března 2018 xxxxxxx xxxxxxxxxxxx (XXX), reakční xxxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxxx, [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxxxx-xxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx-xxxxx, ethylmethylketoximu, xxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxx(α,α-xxxxxxxxxxxxxx)-xxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx xxxxx 2-(1-(diethylaminohydroxyfenyl) xxxxxxxxx)xxxxxxxx, xxxxx 2-[4-(xxxxxxxxxxx)-2-xxxxxxxxxxxxxx]xxxxxxxx.

(3)

Xxxxx xxx o látku xxxxx (xxxxx XXX 7439–92–1 a xxxxxxxx xxxxx 082–013–00–1 (olovo x xxxxxx; [xxxxxx xxxxxx < 1 xx];) x 082–014–00–7 (xxxxxxxx olovo; [xxxxxx xxxxxx ≥ 1 xx];)), XXX ve xxxx stanovisku xx xxx 30. xxxxxxxxx 2018 navrhl použít xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx xx xxxxxxxxx x xxxxxxxxx xxxxx. Xxxxx xxxxxxxx x xxxxx xxxxxxxxx rozpouštění xxxxxxxx xxxxx, xxxxxx xxxxxxxxx xxxxx, xx xxxxxxxxxx xxxxxxx xxxxxx xxxxxx x xxxxxxxx k xxxxx xxxxxxxxxxxxxxx klasifikaci x xxxxxxxxxx x xxxxxxxxxx xxxxx xxxxxx xxxx x xxxxxxxxxxxx xxxxxxxxx x xxxxxxx XX xxxx XXX xxxxxxx xxxxx xxxxxxxxx xxxx, xxx xx xxx xx xxxxxxxxx x xxxxxxxxx formu xxxxx použita xxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx. Kromě xxxx xxxx xxxxxxxxxx xxxx xxxxxxx poznatky, x xxxxx xxxxxxx, xx xxxxxxxxxxxxxxx xxxxxxxxxxx xxx celistvou xxxxx, xxx xx doporučilo xxxxxxxxxx xxxxxx XXX, xxxxxx xxx xxxxxx. Xxxxxxxxxxxxxxx xxxxxxxxxxx xxx xxxxxxxxx xxxxx proto xxxxxx xxxxxxxx xx xxxxxxx XX xxxxxxxx (XX) x. 1272/2008, xxxxx XXX xxxxxx xxx xxxxxxx předložit xxxxxxxxxx xxxxxxxxxx.

(4)

Xxxxx xxx x xxxxx 2-xxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxx, (xxxxx XXX 111-76-2), xxx třídu xxxxxxxxxxxxx „akutní toxicita (xxxxxxxxx)“ xxxx xxxxxxxxxx xxxx vědecké poznatky, xx xxxxxxx vyplývá, xx xxxxxxxxxxx xxx xxxx xxxxx nebezpečnosti xxxxxxxxxxxx xx xxxxxxxxxx xxxxxx XXX, xxx xx xxxxxxx xx xxxxxxxx údajích, xxxxxx xxx vhodná. Xxxx xxxxx nebezpečnosti xx xxxxx neměla xxx x xxxxxxx VI xxxxxxxx (ES) x. 1272/2008 xxxxxxx, dokud XXX xxxxxx mít xxxxxxx xxxxxxxxx x xxxxx novým xxxxxxxxxx xxxxxxxxxx stanovisko; xxxxxxx xxxxxxx třídy xxxxxxxxxxxxx, x xxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxx RAC, xx xxxxxxxx xxx xxxx.

(5)

Xxxxxxxx (XX) x. 1272/2008 xx proto xxxx xxx xxxxxxxxxxxxx xxxxxxxx xxxxxxx.

(6)

Xxxxxxxxxx xxxxxx xxxx aktualizovaných xxxxxxxxxxxxxxx xxxxxxxxxxx xx nemělo xxx, x výhradou xxxxxxxxxxx regulatorních xxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxx xxxxxxxxxx potřebují určitou xxxx xx to, xxx přizpůsobili xxxxxxxxxx x balení xxxxx x směsí xxxxx xxxx revidovaným klasifikacím x xxxxxxx xxxxxxxxx xxxxxx. Xxxx doba xx xxxxxx nezbytná x tomu, xxx xxxxxxxxxx měli xxxxxxxx xxxx xxxxxxxx opatření xxxxx x xxxxxxxxx xxxxxxxx dodržování xxxxxxx xxxxxxxx xxxxxxxxx, xxxxx xxxxxxxx v xxxxxxxx xxxx provedených xxxxx xxxxxx nařízení. Tyto xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx stanovené x xx. 22 xxxx. 1 xxxx. x) xxxxxxxx Xxxxxxxxxx parlamentu x Rady (XX) x. 1907/2006 (3) xxxx xxxxxxxxx xxxxxxxxx x xxxxxx 50 nařízení Xxxxxxxxxx xxxxxxxxxx a Xxxx (XX) x. 528/2012&xxxx;(4).

(7)

Xxxxxxxxxxx by xxxx xxxx být umožněno, xxx xxxxx xxxx xxxxxxxxxx xxxxxxxx xx xxxxxxxxxxx, xxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx xxxx xxxxxxxxxxxxx xxxxxx xxxxxxxx. Xx xx v souladu x xxxxxxxxx podle xx. 61 xxxx. 2 xxxxxxxx (XX) x. 1272/2008,

PŘIJALA TOTO XXXXXXXX:

Článek 1

Xxxxx xxxxxxxx (XX) x. 1272/2008

Xxxxxxx 3 x části 3 přílohy XX xxxxxxxx (ES) x. 1272/2008 se xxxx x xxxxxxx x xxxxxxxx xxxxxx xxxxxxxx.

Xxxxxx 2

Xxxxx x xxxxxxxx x použitelnost

Toto xxxxxxxx xxxxxxxx v xxxxxxxx dvacátým dnem xx xxxxxxxxx x Xxxxxxx xxxxxxxx Evropské xxxx.

Xxxxxxx se ode xxx 1. xxxxxx 2022.

Xxxxxxxx xx druhého xxxxxxxxxxx tohoto článku xxxxx xxx xxxxx x směsi klasifikovány, xxxxxxxxxx x baleny x souladu s xxxxxxxxx (XX) č. 1272/2008 xx xxxxx xxxxxx xxxxxxxx ještě xxxxx xxxx 1. xxxxxx 2022.

Toto xxxxxxxx xx xxxxxxx x xxxxx xxxxxxx x xxxxx xxxxxxxxxx xx všech xxxxxxxxx xxxxxxx.

X Xxxxxxx xxx 19. xxxxxx 2020.

Xx Komisi

Ursula VON XXX LEYEN

předsedkyně

(1)  manaÚř. xxxx. X 353, 31.12.2008, x. 1.

(2)&xxxx;&xxxx;Xxxxxxxxxx xxxx xxxxxxxx na této xxxxxxxxxxx xxxxxxx: https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/

(3)  Nařízení Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) č. 1907/2006 xx dne 18. xxxxxxxx 2006

o xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx x xxxxxxxxx xxxxxxxxxx xxxxx, x zřízení Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx, o xxxxx xxxxxxxx 1999/45/XX x x zrušení xxxxxxxx Xxxx (XXX) x. 793/93, xxxxxxxx Xxxxxx (ES) č. 1488/94, xxxxxxxx Rady 76/769/XXX x xxxxxxx Xxxxxx 91/155/EHS, 93/67/EHS, 93/105/XX a 2000/21/XX (Xx. xxxx. X 396, 30.12.2006, x. 1).

(4)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady (XX) x. 528/2012 xx xxx 22. xxxxxx 2012

x dodávání xxxxxxxxxx xxxxxxxxx xx xxx x xxxxxx xxxxxxxxx

(Xx. xxxx. L 167, 27.6.2012, x. 1).

XXXXXXX

X xxxxxxx XX xxxxxxxx (XX) x. 1272/2008 xx xxxxxxx 3 x části 3 xxxx xxxxx:

1)

Xxxxxxxx xx xxxx xxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx název

Číslo XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx x XXX

Xxxxxxxx

Xxxx tříd a xxxxxxxxx xxxxxxxxxxxxx

Xxxx standardních xxx x nebezpečnosti

Kódy xxxxxxxxxxx xxxxxxx a xxxxxxxxxx xxxx

Xxxx xxxxxxxxxxxx xxx o xxxxxxxxxxxxx

Xxxx xxxxx. xxxxxxxxxxxx vět x nebezpečnosti

„007-030-00-3

kyselina dusičná …% [X ≤ 70 %]

231-714-2

7697-37-2.

Xx. Xxx. 3

Xxxxx Tox. 3

Xxxx Xxxx. 1 X

X272

X331

X314

XXX03

XXX06

XXX05

Xxx

X272

X331

X314

XXX071

Xx. Xxx. 3; X272: X ≥ 65 %

xxxxxxxxx: XXX = 2,65 xx/x (xxxx)

Xxxx Xxxx. 1 X; X314: X ≥ 20 %

Skin Corr. 1X; H314: 5 % ≤ C &xx; 20 %

B“

„014-048-00-5

vlákna x xxxxxxx xxxxxxx (x xxxxxxx < 3 μx, délce &xx; 5 μx x x xxxxxxx xxxxx ≥ 3:1)

206-991-8

409-21-2

308076-74-6

Xxxx. 1X

X350x

XXX08

Xxx

X350x“

„014-049-00-0

xxxxxxxxxxxxxxxxxxxx; xxxxxxxxxx(xxxxx)xxxxx

220-449-8

2768-02-7

Xxxx Sens. 1X

X317

XXX07

Xxx

X317“

„014-050-00-6

xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxx;

6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxx

213-934-0

1067-53-4

Xxxx. 1B

H360FD

GHS08

Dgr

H360FD“

„016-098-00-3

dimethyl-disulfid

210-871-0

624-92-0

Flam. Liq. 2

Xxxxx Xxx. 3

Xxxxx Xxx. 3

XXXX XX 3

XXXX SE 1

Xxx Xxxxx. 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X225

X331

X301

X336

X370 (xxxxx xxxxxxx xxxxx, xxxxxxxxx)

X319

X317

X400

X410

XXX02

XXX06

XXX08

XXX09

Xxx

X225

X331

X301

X336

X370 (xxxxx xxxxxxx cesty, xxxxxxxxx)

X319

X317

X410

xxxxxxxxx: XXX = 5 xx/x (xxxx)

xxxxxx: XXX = 190 xx/xx XX

X = 1

X = 10“

„029-024-00-X

xxxxxxxxxxx xxx;

[xxxxx xxxxxx: xx 0,9 xx a xx 6,0 mm; xxxxx xxxxxx: xx 0,494 xx 0,949 xx]

231-159-6

7440-50-8

Xxxxxxx Xxxxxxx 2

X411

XXX09

X411“

„029-025-00-5

xxx(X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)xxx;

xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxx;

[Xx-XXX]

239-703-4

312600-89-8

15627-09-5

Xxxx. Xxx. 1

Xxxxx Xxx. 4

XXXX RE 2

Eye Xxx. 1

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

H228

H302

H373 (xxxxx)

X318

X400

X410

XXX02

XXX07

XXX08

XXX05

XXX09

Xxx

X228

X302

X373 (xxxxx)

X318

X410

xxxxxx: XXX = 360 xx/xx XX

X = 1

X = 1“

„050-031-00-9

xxxxxxxxxx-xxxxxxxx; [1]

xxxxxxx, xxxxxxx-, xxx(xxxx xxxxxxx) xxxxxxxx [2]

222-883-3 [1] 293-901-5 [2]

3648-18-8 [1] 91648-39-4 [2]

Xxxx. 1X

XXXX XX 1

H360D

H372 (xxxxxxxx xxxxxx)

XXX08

Xxx

X360X

X372 (imunitní systém)“

„601-092-00-0

dibenzo[def,p]chrysen;

dibenzo[a,l]pyren

205-886-4

191-30-0

Carc. 1X

Xxxx. 2

X350

X341

XXX08

Xxx

X350

X341

Xxxx. 1B; X350: X ≥ 0,001 %“

„603-237-00-3

ipkonazol (ISO);

(1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorbenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyklopentanol

–

125225-28-7

115850-69-6

115937-89-8

Repr. 1X

Xxxxx Xxx. 4

XXXX XX 2

Xxxxxxx Xxxxxxx 1

X360X

X302

X373 (oči, kůže, xxxxx)

X410

XXX08

XXX07

XXX09

Xxx

X360X

X302

X373 (xxx, kůže, xxxxx)

X410

xxxxxx: ATE = 500 xx/xx XX

X = 100“

„603-238-00-9

xxx(2-(2-xxxxxxxxxxxxx)xxxxx)-xxxxx; xxxxxxxxx

205-594-7

143-24-8

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„603-239-00-4

xxxxxxxxxxxxx (XXX);

(2XX,3XX)-1-(4-xxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xx

–

76738-62-0

Xxxx. 2

Xxxxx Xxx. 4

Xxxxx Xxx. 4

Xxx Irrit. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X361x

X332

X302

X319

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X332

X302

X319

X410

xxxxxxxxx: ATE = 3,13 xx/x (xxxxx xxxx mlha)

orální: XXX = 490 mg/kg XX

X = 10

M = 10“

„603-240-00-X

2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxx

221-967-7

3296-90-0

Xxxx. 1X

Xxxx. 1X

X350

X340

XXX08

Xxx

X350

X340“

„603-241-00-5

xxxxxxxx;

(2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xx

203-377-1

106-24-1

Xxxx Xxxx. 1

H317

GHS07

Wng

H317“

„605-041-00-3

2-(4-terc-butylbenzyl)propanal

201-289-8

80-54-6

Repr. 1X

X360Xx

XXX08

Xxx

X360Xx“

„607-738-00-8

XXXX-xxxxxxxxx (XXX);

X-xxxxx (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxx; X-xxxxx 4-xxxxx-x-xxxxxxxxxxxxxxxxxx

246-831-4

25319-90-8

Xxxxx Tox. 4

XXXX RE. 2

Xxxxxxx Xxxxx 1 Aquatic Xxxxxxx 1

X302

X373 (xxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxx)

X410

xxxxxx: XXX = 450 xx/xx XX

X = 10

X = 10“

„607-740-00-9

xxxxxxxxxx-xxxxxx

248-523-5

27554-26-3

Xxxx. 1B

H360FD

GHS08

Dgr

H360FD“

„607-741-00-4

4-{[(6-chlorpyridin-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on; xxxxxxxxxxxxxx

–

951659-40-8

Xxxxx Xxx. 4

XXXX XX 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X302

X373 (xxxxxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxxxxxx)

X410

xxxxxx: XXX = 500 mg/kg TH

M = 10

X = 10“

„607-742-00-X

xxxxxxxxxxxxx-xxxxxx (XXX);

xxxxxx-4-[(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxx

–

317815-83-1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1000

M = 1000“

„607-743-00-5

X-(+)-xxxxxx kyselina;

(2 X)-2-xxxxxxxxxxxxxxxx xxxxxxxx

201-196-2

79-33-4

Xxxx Xxxx. 1X

Xxx Xxx. 1

X314

X318

XXX05

Xxx

X314

XXX071“

„607-744-00-0

2-xxxxxxxxxxxxxxxxxxx

221-499-3

3121-61-7

Xxxx. Xxx. 3

Xxxx. 2

Xxxx. 1X

Xxxxx Xxx. 3

Xxxxx Xxx. 4

Xxxx Xxxx. 1X

Xxx Xxx. 1

Skin Xxxx. 1

X226

X341

X360XX

X331

X302

X314

X318

X317

XXX02

XXX05

XXX06

XXX08

Xxx

X226

X341

X360XX

X331

X302

X314

X317

XXX071

xxxxxxxxx: XXX = 2,7 xx/x (xxxx)

xxxxxx: XXX = 404 xx/xx TH“

„607-745-00-6

glyoxylová xxxxxxxx …%

206-058-5

298-12-4

Xxx Xxx. 1

Xxxx Xxxx. 1X

X318

X317

XXX05

XXX07

Xxx

X318

X317

X“

„607-746-00-1

xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxx;

[xxxxxxxxxxx xxxxxxxx x xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx]

274-357-8

70161-44-3

Xxxx. 1X

Xxxx. 2

Xxxxx Tox. 4

Xxxxx Xxx. 4

XXXX SE 3

Xxxx Irrit. 2

Eye Xxxxx. 2

Xxxx Xxxx. 1

X350

X341

X332

X302

X335

X315

X319

X317

XXX08

XXX07

Xxx

X350

X341

X332

X302

X335

X315

X319

X317

xxxxxxxxx: XXX = 3 mg/l (prach xxxx xxxx)

xxxxxx: XXX = 1&xxxx;100 xx/xx XX

8

9“

„611-181-00-6

(xxxxx-XXX-xxxxx)xxxxxxxxxx xxxxxxxx;

xxxxxxxxxxxxxxxxxxxxxxx-1-xxxx, xxxxxxxx xxx;

[X-XXX]

–

66603-10-9

Xxxx. Sol. 1

Acute Xxx. 3

XXXX XX 2

Xxxx Irrit. 2

Eye Xxx. 1

Xxxxxxx Chronic 2

X228

X301

X373 (xxxxx)

X315

X318

X411

XXX02

XXX06

XXX08

XXX05

XXX09

Xxx

X228

X301

X373 (xxxxx)

X315

X318

X411

xxxxxx: XXX = 136 xx/xx XX“

„612-294-00-3

xxxxxxxxxxxxxxxxxxxxx;

X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxx;

xxxxxxxxxxx-xxxxx-xxxxxx;

[XXX]

221-106-5

3006-10-8

Xxxx Xxxx. 1

Xxx Xxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X314

X318

X400

X410

XXX05

XXX09

Xxx

X314

X410

XXX071

X = 100

X = 1&xxxx;000 “

„613-331-00-6

(2XX)-2-[4-(4-xxxxxxxxxxx)-2-(xxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xx;

xxxxxxxxxxxxxxxxxx

–

1417782-03-6

Xxxx Xxxx. 1

Xxxxxxx Acute 1

Xxxxxxx Chronic 1

X317

X400

X410

XXX07

XXX09

Xxx

X317

X410

X = 1

X = 1“

„613-332-00-1

xxxxxxxxxxxxxxx (ISO);

1-(4-{4-[5-(2,6-difluorfenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluormethyl)-1H-pyrazol-1-yl]ethanon

–

1003318-67-9

Aquatic Xxxxxxx 1

X410

XXX09

Xxx

X410

X = 1“

„613-333-00-7

xxxxxxxxx-xxxxx; (X-4)-xxx[1-(xxxxxxx-.xxxxx.X)xxxxxxx-2(1X)-xxxxxxxx-.xxxxx.X]xxxxx

236-671-3

13463-41-7

Xxxx. 1X

Xxxxx Xxx. 2

Xxxxx Xxx. 3

STOT XX 1

Eye Xxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360X

X330

X301

X372

X318

X400

X410

XXX08

XXX06

XXX05

XXX09

Xxx

X360X

X330

X301

X372

X318

X410

xxxxxxxxx: ATE = 0,14 xx/x (xxxxx nebo mlha)

orální: XXX = 221 xx/xx XX

X = 1&xxxx;000

X = 10“

„613-334-00-2

xxxxxxxxxxxxxx (XXX);

3-xxxxx-4-(xxxxxxxxxxx)-1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xx

262-661-3

61213-25-0

Xxxx. 1B

Acute Xxx. 4

Xxxx Xxxx. 1

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360XX

X302

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X360XX

X302

X317

X410

xxxxxx: ATE = 500 mg/kg XX

X = 100

X = 100“

„613-335-00-8

4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xx; [DCOIT]

264-843-8

64359-81-5

Acute Xxx. 2

Xxxxx Xxx. 4

Xxxx Xxxx. 1

Eye Xxx. 1

Xxxx Xxxx. 1 X

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

X330

X302

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X302

X314

X317

X410

XXX071

xxxxxxxxx: XXX = 0,16 xx/x (xxxxx nebo xxxx)

xxxxxx: XXX = 567 xx/xx XX

Xxxx Xxxxx. 2; X315: 0,025 % ≤ X &xx; 5 %

Xxx Xxxxx. 2; H319: 0,025 % ≤ X < 3 %

Xxxx Xxxx. 1 X; X317: X ≥ 0,0015 %

M = 100

M = 100“

„613-336-00-3

2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx;

[XXXX]

–

2527-66-4

Xxxxx Xxx. 4

Xxxxx Xxx. 3

Xxxx Corr. 1X

Xxx Dam. 1

Xxxx Xxxx. 1 X

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 2

X312

X301

X314

X318

X317

X400

X411

XXX06

XXX05

XXX09

Xxx

X312

X301

X314

X317

X410

XXX071

xxxxxxxx: XXX = 1&xxxx;100 xx/xx TH

orální: XXX = 175 xx/xx XX

Xxxx Xxxx. 1 X; X317: X ≥ 0,0015 %

X = 1“

„616-228-00-4

3-(difluormethyl)-1-methyl-N-(3‘,4’,5’-trifluorbifenyl-2-yl)pyrazol-4-karboxamid;

fluxapyroxad

–

907204-31-3

Lact.

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

X362

X400

X410

XXX09

Xxx

X362

X410

X = 1

X = 1“

„616-230-00-5

X-(xxxxxxxxxxxxx)xxxxxxxxx; xxxxxxxxxxxxxxxxx; [XXX]

213-103-2

924-42-5

Xxxx. 1X

Xxxx. 1B

STOT XX 1

X350

X340

X372 (xxxxxxxxx xxxxxxx xxxxxx)

XXX08

Xxx

X350

X340

X372 (periferní xxxxxxx xxxxxx)“

„616-231-00-0

5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxx; 2’-[(RS)-1,3-dimethylbutyl]-5-fluor-1,3-dimethylpyrazol-4-karboxanilid;

penflufen

–

494793-67-8

Carc. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H351

H400

H410

GHS08

GHS09

Wng

H351

H410

M = 1

X = 1“

„616-232-00-6

iprovalikarb (XXX);

xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxx

–

140923-17-7

Xxxx. 2

X351

XXX08

Xxx

X351“

„616-233-00-1

xxxxxxxxxx (XXX);

X-xxxxx-4,5-xxxxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxx

–

175217-20-6

XXXX XX 2

Aquatic Xxxxxxx 2

X373

X411

XXX08

XXX09

Xxx

X373

X411“

„650-057-00-6

Xxxxxxx, xxxxxxx [xxxx lisovaný za xxxxxxx ze xxxxx xxxxxxxx Azadirachta xxxxxx xxx skořápek, extrahovaný xxxxxxxxxxxxxx xxxxxx uhličitým]

283-644-7

84696-25-3

Aquatic Xxxxxxx 3

X412

X412“

2)

xxxxxxx odpovídající xxxxxxxxx xxxxxx 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616–014–00–0 x 617–006–00-X xx xxxxxxxxx xxxxxx položkami:

Indexové xxxxx

Xxxxxxxx xxxxx

Xxxxx XX

Xxxxx CAS

Klasifikace

Označení

Specifické xxxxxxx. xxxxxx, multiplikační xxxxxxx a ATE

Poznámky

Kódy xxxx x kategorií xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx výstražných xxxxxxx x signálních xxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxx. xxxxxxxxxxxx vět o xxxxxxxxxxxxx

„007-004-00-1

xxxxxxxx xxxxxxx …% [X &xx; 70 %]

231-714-2

7697-37-2

Xx. Liq. 2

Xxxxx Xxx. 1

Xxxx Xxxx. 1 X

X272

X330

X314

XXX03

XXX06

XXX05

Xxx

X272

X330

X314

XXX071

Xx. Liq. 2; H272: X ≥ 99 %

Xx. Xxx. 3; X272: 70 % ≤ X &xx; 99 %

X“

„014-018-00-1

xxxxxxxxxxxxxxxxxxxxxxxxxxx;

[X4]

209-136-7

556-67-2

Xxxx. 2

Xxxxxxx Chronic 1

X361x ***

X410

XXX08

XXX09

Xxx

X361x ***

X410

X = 10“

„015-134-00-5

xxxxxxxxx-xxxxxx (ISO);

O-[2-(diethylamin)-6-methylpyrimidin-4-yl]-O,O-dimethyl-fosforothioát

249-528-5

29232-93-7

Acute Xxx. 4

STOT XX 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

H302

H372 (xxxxxxx xxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X372 (xxxxxxx xxxxxx)

X410

xxxxxx: XXX = 1&xxxx;414 xx/xx XX

X = 1&xxxx;000

X = 1&xxxx;000 “

„015-181-00-1

xxxxxx

232-260-8

7803-51-2

Xxxx. Xxx 1

Xxxxx. Xxx

Xxxxx Xxx. 1

Xxxx Xxxx. 1B

Aquatic Xxxxx 1

X220

X330

X314

X400

XXX02

XXX04

XXX06

XXX05

XXX09

Xxx

X220

X330

X314

X400

xxxxxxxxx:

XXX = 10 xxxX (xxxxx)

X“

„050-021-00-4

xxxxxxxxxxxxxxxxxxxxx

222-583-2

3542-36-7

Xxxx. 1B

Acute Xxx. 2

STOT RE 1

Xxxxxxx Chronic 3

H360D

H330

H372 **

X412

XXX08

XXX06

Xxx

X360X

X330

X372 **

X412

Xxxx. 1X; X360 D: C ≥ 0,03 %

inhalační: XXX = 0.098 xx/X (xxxxx xxxx xxxx)“

„050-027-00-7

2-xxxxxxxxxx 10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxxxxxxxxxx; [XXXX]

239-622-4

15571-58-1

Xxxx. 1X

XXXX XX 1

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360X

X372 (xxxxxxxx xxxxxx)

X400

X410

XXX08

XXX09

Xxx

X360X

X372 (xxxxxxxx systém)

H410“

„082-013-00-1

olověný xxxxxx; [xxxxxx částic &xx; 1 xx]

231-100-4

7439-92-1

Xxxx. 1 X

Xxxx.

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H360FD

H362

H400

H410

GHS08

GHS09

Dgr

H360FD H362

H410

Repr. 1 A; X360X: X ≥ 0,03 %

X = 1

X = 10“

„603-014-00-0

2-xxxxxxxxxxx-1-xx;

xxxxxxxxxxxxxxxxxxxxxxxxxxxx

203-905-0

111-76-2

Xxxxx Tox. 4*

Xxxxx Xxx. 4

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

X332

X302

X315

X319

XXX07

Xxx

X332

X302

X315

X319

xxxxxx: XXX = 1&xxxx;200 xx/xx XX“

„603-065-00-9

x-xxx(2,3-xxxxxxxxxxxx)xxxxxx;

xxxxxxxxxxxxxxxxxxxxxxxxx

202-987-5

101-90-6

Xxxx. 1X

Xxxx. 2

Xxxxx Xxx. 3

Xxxxx Xxx. 4

Xxxx Xxxxx. 2

Eye Xxxxx. 2

Xxxx Sens. 1

Xxxxxxx Xxxxxxx 3

X350

X341

X311

X302

X315

X319

X317

X412

XXX08

XXX06

Xxx

X350

X341

X311

X302

X315

X319

X317

X412

xxxxxxxx: ATE = 300 xx/xx XX orální: ATE = 500 xx/xx XX“

„607-177-00-9

xxxxxxxxxx-xxxxxx (XXX);

xxxxxx-2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxx

401-190-1

101200-48-0

XXXX XX 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X373

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X373

X317

X410

X = 100

X = 100“

„607-256-00-8

xxxxxxxxxxxx (XXX);

xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxx

–

131860-33-8

Xxxxx Tox. 3

Aquatic Xxxxx 1

Aquatic Chronic 1

X331

X400

X410

XXX06

XXX09

Xxx

X331

X410

xxxxxxxxx:

XXX = 0,7 xx/x (prach xxxx xxxx)

X = 10

X = 10“

„607-314-00-2

xxxxxxxxxxx (XXX);

(XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx xxxxxxxxxxxxxx

247-525-3

26225-79-6

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„609-041-00-4

2,4-xxxxxxxxxxxx

200-087-7

51-28-5

Xxxxx Xxx. 3 *

Acute Xxx. 3

Acute Xxx. 2

XXXX XX 1

Xxxxxxx Xxxxx 1

X331

X311

X300

X372

X400

XXX06

XXX08

XXX09

Xxx

X331

X311

X300

X372

X400

xxxxxxxx: XXX = 300 xx/xx XX xxxxxx: ATE = 30 mg/kg XX“

„609-064-00-X

xxxxxxxxx (ISO);

2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyklohexandion

–

104206-82-8

Repr. 2

XXXX XX 2

Xxxxxxx Acute 1

Xxxxxxx Chronic 1

X361x

X373 (xxx, nervový systém)

H400

H410

GHS08

GHS09

Wng

H361d

H373 (xxx, nervový xxxxxx)

X410

X = 10

M = 10“

„613-112-00-5

xxxxxxxxxx (ISO);

2-oktyl-2H-isothiazol-3-on; [XXX]

247-761-7

26530-20-1

Xxxxx Xxx. 2

Acute Xxx. 3

Xxxxx Xxx. 3

Xxxx Xxxx. 1

Eye Xxx. 1

Xxxx Xxxx. 1 X

Xxxxxxx Acute 1 Xxxxxxx Xxxxxxx 1

H330

H311

H301

H314

H318

H317

H400

H410

GHS06

GHS05

GHS09

Dgr

H330

H311

H301

H314

H317

H410

EUH071

inhalační: XXX = 0,27 xx/x (xxxxx xxxx xxxx)

xxxxxxxx: XXX = 311 xx/xx TH xxxxxx: ATE = 125 xx/xx XX

Xxxx Xxxx. 1 A; X317: X ≥ 0,0015 %

X = 100

X = 100“

„613-115-00-1

xxxxxxxxx (XXX);

3-xxxxxxx-5-xxxxxxxxxxxxxx

233-000-6

10004-44-1

Xxxx. 2

Xxxxx Xxx. 4

Xxx Xxx. 1

Skin Xxxx. 1

Aquatic Xxxxxxx 2

X361x

X302

X318

X317

X411

XXX08

XXX07

XXX05

XXX09

Xxx

X361x

X302

X318

X317

X411

xxxxxx: XXX = 1&xxxx;600 mg/kg XX“

„613-125-00-6

xxxxxxxxxxx (XXX);

xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxx

–

78587-05-0

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H400

H410

GHS09

Wng

H410

M = 1

X = 1“

„613-202-00-4

xxxxxxxxxx (XXX);

(X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxxxxxxxx)-1,2,4-xxxxxxx-3(2X)-xx

–

123312-89-0

Xxxx. 2

Xxxx. 2

Aquatic Xxxxxxx 1

H351

H361fd

H410

GHS08

GHS09

Wng

H351

H361fd

H410

M = 1“

„613-259-00-5

xxxxxxxxxxx (XXX);

xxxxxxx xxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxx; [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxxxx-xxxxxxxxxxxxx

428-790-6

72963-72-5

Xxxx. 2

Xxxxx Xxx. 4

Xxxxx Xxx. 4

XXXX SE 2

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X351

X332

X302

X371 (xxxxxxx xxxxxx; xxxxxx, xxxxxxxxx)

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X332

X302

X371 (xxxxxxx xxxxxx; orální, inhalační)

H410

inhalační: XXX = 1,4 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 550 xx/xx XX

X = 10

X = 10“

„616-014-00-0

xxxxx-xx-xxxx; xxxxxxxxxxxxxxxxxx, xxxxx(xxxxxx)xxxxxxxxx

202-496-6

96-29-7

Xxxx. 1X

Xxxxx Tox. 4

Xxxxx Xxx. 3

STOT XX 3

XXXX SE 1

XXXX XX 2

Skin Xxxxx. 2

Xxx Xxx. 1

Skin Xxxx. 1

X350

X312

X301

X336

X370 (xxxxx xxxxxxx xxxxx)

X373 (xxxxxx xxxx)

X315

X318

X317

XXX08

XXX06

XXX05

Xxx

X350

X312

X301

X336

X370 (horní xxxxxxx xxxxx)

X373 (xxxxxx xxxx)

X315

X318

X317

xxxxxxxx: XXX = 1 100 xx/xx TH orální: XXX = 100 xx/xx XX“

„617-006-00-X

xxx(α,α-xxxxxxxxxxxxxx)xxxxxxx

201-279-3

80-43-3

Xxx. Xxxxx. X

Xxxx. 1B

Skin Xxxxx. 2

Xxx Irrit. 2

Xxxxxxx Xxxxxxx 2

H242

H360D

H315

H319

H411

GHS02

GHS08

GHS07

GHS09

Dgr

H242

H360D

H315

H319

H411“

3)

položky xxxxxxxxxxxx xxxxxxxxx xxxxxx 601-064-00-8 x 607-693-00-4 xx xxxxxxx.